Systemic hematologic status following intraventricular recombinant tissue-type plasminogen activator for intraventricular hemorrhage: the CLEAR IVH Study Group.
Stroke
; 42(12): 3631-3, 2011 Dec.
Article
em En
| MEDLINE
| ID: mdl-21940973
ABSTRACT
BACKGROUND AND PURPOSE:
This is the first prospective evaluation of changes in systemic hematologic status following administration of intraventricular recombinant tissue-type plasminogen activator in patients with intraventricular hemorrhage (IVH).METHODS:
Laboratory data from subjects enrolled onto the Clot Lysis Evaluating Accelerated Resolution of IVH (CLEAR IVH) Trials were analyzed. We analyzed pre- and post- recombinant tissue-type plasminogen activator dosing coagulation parameters. Longer-term changes in hematologic status were studied in subjects who received the study agent after blood clot in the third/fourth ventricles had resolved radiologically.RESULTS:
Plasma fibrinogen increased significantly in both treatment groups. Dosing did not have a significant impact on any systemic coagulation parameters in either treatment group.CONCLUSIONS:
Intraventricular recombinant tissue-type plasminogen activator is unlikely to impact systemic coagulation or to compound the effects of systemic anticoagulation for deep venous thrombosis prophylaxis. CLINICAL TRIAL REGISTRATION URL http//clinicaltrials.gov. Unique identifier NCT00650858.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Coagulação Sanguínea
/
Terapia Trombolítica
/
Hemorragia Cerebral
/
Ativador de Plasminogênio Tecidual
Tipo de estudo:
Observational_studies
/
Prognostic_studies
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2011
Tipo de documento:
Article